Recursion Pharmaceuticals (RXRX) Income towards Parent Company (2020 - 2026)

Recursion Pharmaceuticals' Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$117.5 million for Q1 2026.

• Quarterly Income towards Parent Company rose 41.97% year-over-year to -$117.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$559.8 million (up 2.61% YoY) and the FY2025 annual result came in at -$644.8 million, down 39.06% from the prior year.
• Income towards Parent Company was -$117.5 million for Q1 2026 at Recursion Pharmaceuticals, down from -$108.1 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$56.0 million in Q1 2022 and bottomed at -$202.5 million in Q1 2025.
• A 5-year average of -$106.1 million and a median of -$93.0 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2025 — Income towards Parent Company sank 121.6% — and 2026, when it soared 41.97%.
• Recursion Pharmaceuticals' Income towards Parent Company stood at -$64.5 million in 2022, then plunged by 44.09% to -$93.0 million in 2023, then sank by 92.38% to -$178.9 million in 2024, then soared by 39.56% to -$108.1 million in 2025, then declined by 8.68% to -$117.5 million in 2026.
• Business Quant data shows RXRX's Income towards Parent Company at -$117.5 million in Q1 2026, -$108.1 million in Q4 2025, and -$162.3 million in Q3 2025.